Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.

Shivaji, Uday N and Sharratt, Caroline L and Thomas, Tom and Smith, Samuel C L and Iacucci, Marietta and Moran, Gordon W and Ghosh, Subrata and Bhala, Neeraj (2019) Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Alimentary pharmacology & therapeutics, 49 (6). pp. 664-680. ISSN 1365-2036. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

[img]
Preview
Text
Shivaji_et_al-2019-Alimentary_Pharmacology_&_Therapeutics.pdf

Download (652kB) | Preview
Official URL: https://onlinelibrary.wiley.com/doi/full/10.1111/a...

Abstract

BACKGROUND

Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF monoclonal antibodies are increasingly used. Anti-TNF therapies are widely used and their adverse effects are well characterised, and may cause significant morbidity and mortality in a small proportion of exposed patients. Gastroenterologists need to understand the mechanisms for these effects, recognise these swiftly and manage such events appropriately.

AIM

To cover the range of potential adverse reactions as a result of biologic therapy and specifically management of these events.

METHODS

A Medline and Pubmed search was undertaken. Search terms included were "anti-TNF," "infliximab" or "adalimumab" or "golimumab" combined with the keywords "ulcerative colitis" or "Crohn's disease" or "inflammatory bowel disease" and then narrowed to articles containing the keywords "complications," "side effects" or "adverse events" or "safety profile." International guidelines were also reviewed where relevant.

RESULTS

Adverse events discussed in this review include infusion reactions, blood disorders and infections (including bacterial, viral, fungal and opportunistic infections) as well as autoimmune, dermatological disorders, cardiac and neurological conditions. Malignancies including solid organ, haematological and those linked to viral disease are discussed.

CONCLUSIONS

Anti-TNF therapy has wide-ranging effects on the immune system resulting in a spectrum of potential adverse events in a small proportion of patients. Research advances are improving the understanding, recognition and management of these adverse events.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: WI Digestive system. Gastroenterology
Divisions: Planned IP Care > Gastroentrology
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 19 Mar 2019 12:36
Last Modified: 19 Mar 2019 12:36
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/1938

Actions (login required)

View Item View Item